AIM ImmunoTech Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Continued progress across pipeline programs with focus on pancreatic cancer

Mid-year report of Ampligen^® (rintatolimod) in combination with AstraZeneca’s Imfinzi^® (durvalumab) for the treatment of pancreatic cancer demonstrates promising signs of both no significant toxicity and superior PFS and OS

Read more at globenewswire.com